New ad hoc reporting tool offers easy user interface to facilitate more in-depth data capture and broad graphical presentations
San Ramon, CA – March 30, 2009 –
Nextrials, Inc., a leader in clinical research software and services, today announced that its award-winning Prism® data capture and clinical trial management platform has increased its report generation functionality to deliver more powerful data mining capabilities to customers. With the improved ad hoc reporting feature, users can now collect, summarize and export data from tables within a single study or across multiple studies, creating efficiencies that save time and lower study costs. Its user-friendly graphical interface also includes advanced interactive data view formats, such as heat maps, in addition to bar graphs, pie charts and other standard visual templates.
These new reporting features are tightly integrated within Prism (no separate log-ins are required). Product highlights are:
- an intuitive user interface
- preview panes to help users visualize reports in progress
- broad, interactive graphical tools
- enhanced export capabilities
- concomitant medication and adverse event coding data integration
Visitors to the 18th annual Partnerships with CROs, being held April 28-30 at the Rosen Shingle Creek Hotel in Orlando, FL, can see a demonstration of Prism with its enhanced reporting functionality in booth #601.
“Prism continues to evolve in tandem with our customers’ needs,” noted Robert Barr, chief technology officer at Nextrials. “With the growing complexity of clinical trials, it’s important for researchers to be able to generate reports customized for numerous audiences, ranging from safety analysts to clinicians. Prism’s enhanced reporting capabilities make it easier to both compile trial data and drill down on data points of interest, providing better visibility of study results, and reducing the opportunity for error.”
Nextrials’ award-winning Prism melds sophisticated clinical trial management functionality with electronic data capture in a single, integrated package. It is currently used worldwide by biopharmaceutical and medical device R&D teams developing novel treatments and therapeutics.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,000 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit
www.nextrials.com
or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at
http://pharmavoice.com/podcasts
.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.